U.S. Markets closed

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
40.58+3.61 (+9.76%)
At close: 4:00PM EDT
People also watch

Opiant Pharmaceuticals, Inc.

401 Wilshire Boulevard
12th Floor
Santa Monica, CA 90401
United States

IndustryApplication Software
Full Time Employees5

Key Executives

Dr. Michael J. Sinclair M.D.Exec. ChairmanN/AN/A74
Dr. Roger Crystal M.D.CEO, Pres & DirectorN/AN/A41
Mr. Kevin A. Pollack J.D., Esq., M.B.A.CFO, Treasurer & Sec.1.17MN/A47
Dr. Phil Skolnick Ph.D., D.Sc. (hon)Chief Scientific OfficerN/AN/A70
Mr. Quan VuVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.

Corporate Governance

Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.